Literature DB >> 29546505

An efficient model for auxiliary diagnosis of hepatocellular carcinoma based on gene expression programming.

Li Zhang1, Jiasheng Chen2, Chunming Gao2, Chuanmiao Liu2, Kuihua Xu2.   

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. The early diagnosis of HCC is greatly helpful to achieve long-term disease-free survival. However, HCC is usually difficult to be diagnosed at an early stage. The aim of this study was to create the prediction model to diagnose HCC based on gene expression programming (GEP). GEP is an evolutionary algorithm and a domain-independent problem-solving technique. Clinical data show that six serum biomarkers, including gamma-glutamyl transferase, C-reaction protein, carcinoembryonic antigen, alpha-fetoprotein, carbohydrate antigen 153, and carbohydrate antigen 199, are related to HCC characteristics. In this study, the prediction of HCC was made based on these six biomarkers (195 HCC patients and 215 non-HCC controls) by setting up optimal joint models with GEP. The GEP model discriminated 353 out of 410 subjects, representing a determination coefficient of 86.28% (283/328) and 85.37% (70/82) for training and test sets, respectively. Compared to the results from the support vector machine, the artificial neural network, and the multilayer perceptron, GEP showed a better outcome. The results suggested that GEP modeling was a promising and excellent tool in diagnosis of hepatocellular carcinoma, and it could be widely used in HCC auxiliary diagnosis. Graphical abstract The process to establish an efficient model for auxiliary diagnosis of hepatocellular carcinoma.

Entities:  

Keywords:  Auxiliary diagnosis; Gene expression programming; Hepatocellular carcinoma; Serum biomarkers

Mesh:

Substances:

Year:  2018        PMID: 29546505     DOI: 10.1007/s11517-018-1811-6

Source DB:  PubMed          Journal:  Med Biol Eng Comput        ISSN: 0140-0118            Impact factor:   2.602


  32 in total

1.  Entering the black box of neural networks.

Authors:  P S Heckerling; B S Gerber; T G Tape; R S Wigton
Journal:  Methods Inf Med       Date:  2003       Impact factor: 2.176

2.  Molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Snorri S Thorgeirsson; Joe W Grisham
Journal:  Nat Genet       Date:  2002-08       Impact factor: 38.330

Review 3.  Significant biomarkers for the management of hepatocellular carcinoma.

Authors:  Yasuteru Kondo; Osamu Kimura; Tooru Shimosegawa
Journal:  Clin J Gastroenterol       Date:  2015-04-09

4.  Treatment of early hepatocellular carcinoma: Towards personalized therapy.

Authors:  Silvia Tremosini; María Reig; Carlos Rodríguez de Lope; Alejandro Forner; Jordi Bruix
Journal:  Dig Liver Dis       Date:  2010-07       Impact factor: 4.088

5.  Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment.

Authors:  Hiroyuki Nakanishi; Masayuki Kurosaki; Kaoru Tsuchiya; Yutaka Yasui; Mayu Higuchi; Tsubasa Yoshida; Yasuyuki Komiyama; Kenta Takaura; Tsuguru Hayashi; Konomi Kuwabara; Natsuko Nakakuki; Hitomi Takada; Masako Ueda; Nobuharu Tamaki; Shoko Suzuki; Jun Itakura; Yuka Takahashi; Namiki Izumi
Journal:  Liver Cancer       Date:  2016-09-14       Impact factor: 11.740

Review 6.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 7.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

8.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Authors:  Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

9.  Lung cancer prediction from microarray data by gene expression programming.

Authors:  Hasseeb Azzawi; Jingyu Hou; Yong Xiang; Russul Alanni
Journal:  IET Syst Biol       Date:  2016-10       Impact factor: 1.615

10.  Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients.

Authors:  Hie-Won Hann; Shaogui Wan; Ronald E Myers; Richard S Hann; Jinliang Xing; Bicui Chen; Hushan Yang
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

View more
  3 in total

1.  The Predictive Efficacy of Serum Exosomal microRNA-122 and microRNA-148a for Hepatocellular Carcinoma Based on Smart Healthcare.

Authors:  Peng Deng; Mi Li; Yuni Wu
Journal:  J Healthc Eng       Date:  2022-01-04       Impact factor: 2.682

2.  Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization.

Authors:  Qiao Ke; Fu Xiang; Chunhong Xiao; Qizhen Huang; Xiaolong Liu; Yongyi Zeng; Lei Wang; Jingfeng Liu
Journal:  BMC Cancer       Date:  2021-10-18       Impact factor: 4.430

3.  Distinctive pattern of AHNAK methylation level in peripheral blood mononuclear cells and the association with HBV-related liver diseases.

Authors:  Libo Sun; Kang Li; Guihai Liu; Yuan Xu; Aiying Zhang; Dongdong Lin; Haitao Zhang; Xiaofei Zhao; Boxun Jin; Ning Li; Yonghong Zhang
Journal:  Cancer Med       Date:  2018-09-27       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.